Nasal Vaccine for Alzheimer’s Disease Enters Clinical Trial
Recently, Brigham and Women’s Hospital in Boston launched the first human trial of a nasal vaccine for Alzheimer’s disease. Nearly 20 years of research went into developing the vaccine, which uses the immune system to clear Alzheimer’s disease-related proteins from the brain. Lead researcher Dr. Howard Weiner discusses the science behind the vaccine and how it could introduce new ways of treating other neurodegenerative diseases in the future.
